Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review

  • Bogdan ObrișcăEmail author
  • Roxana Jurubiță
  • Bogdan Sorohan
  • Laura Iliescu
  • Cătălin Baston
  • Raluca Bobeică
  • Andreea Andronesi
  • Nicolae Leca
  • Gener Ismail
Case Based Review


Newer treatment protocols involving direct-acting antiviral agents (DAAs) have been associated with high rates of sustained virologic response (SVR) and clinical remission in patients with hepatitis C virus (HCV) associated cryoglobulinemic vasculitis (HCV-CV), but clinical response in those with renal involvement is less clear. Our goal was to evaluate the clinical course following DAA therapy in one of the largest cohorts of patients with HCV-associated cryoglobulinemic glomerulonephritis (HCV-GN) reported to date. This is an observational study of patients with chronic HCV infection and circulating cryoglobulins (CC) treated with DAAs in our department from January 2015 to January 2019. We identified a total of 67 patients with HCV and CC out of which nine patients fulfilled the criteria of HCV-GN and had adequate clinical follow-up time. We describe a cohort of nine patients with a mean age of 57 years and known duration of HCV infection ranging 3–20 years (four with evidence of compensated cirrhosis). All patients received the ritonavir-boosted paritaprevir/ombitasvir/dasabuvir regimen for 12 weeks and achieved SVR without subsequent viral relapse. Following DAAs completion, one patient developed “new-onset” cryoglobulinemic glomerulonephritis, six showed either persistent or worsening glomerulonephritis, and only two patients had a complete clinical response (CCR). Of the six patients with either persistent or worsening CV, 67% received additional immunosuppressive (IS) therapy for uncontrolled CV. Of the two patients that had a CCR, one patient received prior IS therapy while the other one improved without any additional intervention. Newer HCV treatment protocols involving DAAs are highly successful in eradication of HCV infection; however, in our experience, DAA treatment alone is insufficient in improving the renal outcomes of patients with HCV-GN and additional IS therapies should be considered.


Cryoglobulinemia Direct-acting antiviral agents Glomerulonephritis Hepatitis C virus Immunosuppression 


Compliance with ethical standards

The study was conducted after institutional approval (The Ethics Committee of Fundeni Clinical Institute, Registration Number, 23249) aligned with the provisions of the Declaration of Helsinki and written consent to participate in the study was provided by all participating patients.




  1. 1.
    Charles ED, Dustin LB (2009) Hepatitis C virus-induced cryoglobulinemia. Kidney Int 76(8):818–824. CrossRefGoogle Scholar
  2. 2.
    Bunchorntavakul C, Mitrani R, Reddy KR (2018) Advances in HCV and cryoglobulinemic vasculitis in the era of DAAs: are we at the end of the road? J Clin Exp Hepatol 2017:1–14. Google Scholar
  3. 3.
    Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G, Confalonieri R, Tarantino A, Pasquali S, Amoroso A, Savoldi S, Colombo V, Manno C, Ponzetto A, Moriconi L, Pani A, Rustichelli R, di Belgiojoso GB, Comotti C, Quarenghi MI (2007) Multicenter study on hepatitis C virus–related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49(1):69–82. CrossRefGoogle Scholar
  4. 4.
    Roccatello D, Sciascia S, Rossi D, Solfietti L, Fenoglio R, Menegatti E, Baldovino S (2017) The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget. 8(25):41764–41777. CrossRefGoogle Scholar
  5. 5.
    Jadoul M, Berenguer MC, Doss W, Fabrizi F, Izopet J, Jha V, Kamar N, Kasiske BL, Lai CL, Morales JM, Patel PR, Pol S, Silva MO, Balk EM, Gordon CE, Earley A, di M, Martin P (2018) Executive summary of the 2018 KDIGO hepatitis C in CKD guideline: welcoming advances in evaluation and management. Kidney Int 94:663–673. CrossRefGoogle Scholar
  6. 6.
    Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J, Adler SG, Alpers CE, Ayoub I, Bagga A, Barbour SJ, Barratt J, Chan DTM, Chang A, Choo JCJ, Cook HT, Coppo R, Fervenza FC, Fogo AB, Fox JG, Glassock RJ, Harris D, Hodson EM, Hogan JJ, Hoxha E, Iseki K, Jennette JC, Jha V, Johnson DW, Kaname S, Katafuchi R, Kitching AR, Lafayette RA, Li PKT, Liew A, Lv J, Malvar A, Maruyama S, Mejía-Vilet JM, Mok CC, Nachman PH, Nester CM, Noiri E, O’Shaughnessy MM, Özen S, Parikh SM, Park HC, Peh CA, Pendergraft WF, Pickering MC, Pillebout E, Radhakrishnan J, Rathi M, Ronco P, Smoyer WE, Tang SCW, Tesař V, Thurman JM, Trimarchi H, Vivarelli M, Walters GD, Wang AYM, Wenderfer SE, Wetzels JFM (2019) Management and treatment of glomerular diseases (part 2): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 95(part 2):281–295. CrossRefGoogle Scholar
  7. 7.
    Guo S, Wietecha TA, Hudkins KL, Kida Y, Spencer MW, Pichaiwong W, Kojima I, Duffield JS, Alpers CE (2011) Macrophages are essential contributors to kidney injury in murine cryoglobulinemic membranoproliferative glomerulonephritis. Kidney Int 80(9):946–958. CrossRefGoogle Scholar
  8. 8.
    Ito M, Murakami K, Suzuki T, Mochida K, Suzuki M, Ikebuchi K, Yamaguchi K, Mizuochi T (2010) Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol 135(3):459–465. CrossRefGoogle Scholar
  9. 9.
    Roccatello D, Isidoro C, Mazzucco G, Mesiti A, Quattrocchio G, Amore A, Molino A, Coppo R, Sena LM, Piccoli G (1993) Role of monocytes in cryoglobulinemia-associated nephritis. Kidney Int 43(5):1150–1155. CrossRefGoogle Scholar
  10. 10.
    Roccatello D, Morsica G, Picciotto G et al (1997) Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinaemia and hepatitis C virus (HCV) infection. Clin Exp Immunol 110(1):9–14. CrossRefGoogle Scholar
  11. 11.
    Bonacci M, Lens S, Mariño Z, Londoño MC, Rodriguez-Tajes S, Sánchez-Tapias JM, Ramos-Casals M, Hernández-Rodríguez J, Forns X (2018) Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterology. 155(2):311–315.e6. CrossRefGoogle Scholar
  12. 12.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11. CrossRefGoogle Scholar
  13. 13.
    Pawlotsky J, Negro F, Aghemo A et al (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol.
  14. 14.
    Dammacco F, Sansonno D (2013) Therapy for hepatitis C virus–related cryoglobulinemic vasculitis. N Engl J Med 369:1035–1045. CrossRefGoogle Scholar
  15. 15.
    Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT (2016) Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 63(2):408–417. CrossRefGoogle Scholar
  16. 16.
    Dammacco F, Tucci FA, Lauletta G, Gatti P, de Re V, Conteduca V, Sansonno S, Russi S, Mariggio MA, Chironna M, Sansonno D (2010) Pegylated interferon, ribavirin, and rituximab combined therapy of hepatitis C virus – related mixed cryoglobulinemia : a long-term study. Blood. 116(3):343–353. CrossRefGoogle Scholar
  17. 17.
    Makara M, Sulyok M, Csacsovszki O, Sulyok Z, Vályi-nagy I (2015) Successful treatment of HCV-associated cryoglobulinemia with ombitasvir / paritaprevir / ritonavir , dasabuvir and ribavirin : a case report. J Clin Virol 72:66–68. CrossRefGoogle Scholar
  18. 18.
    Saadoun D, Thibault V, Nafa S et al (2015) Sofosbuvir plus ribavirin for hepatitis C virus- associated cryoglobulinaemia vasculitis : VASCUVALDIC study. Ann Rheum Dis 75:1–6. Google Scholar
  19. 19.
    Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL (2015) Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series. Postgrad Med 127(4):413–417. CrossRefGoogle Scholar
  20. 20.
    Obata F, Murakami T, Miyagi J, Ueda S, Inagaki T, Minato M, Ono H, Nishimura K, Shibata E, Tamaki M, Yoshimoto S, Kishi F, Kishi S, Matsuura M, Nagai K, Abe H, Doi T (2017) A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant. CEN Case Reports 6(1):55–60. CrossRefGoogle Scholar
  21. 21.
    Gragnani L, Visentini M, Fognani E, Urraro T, de Santis A, Petraccia L, Perez M, Ceccotti G, Colantuono S, Mitrevski M, Stasi C, del Padre M, Monti M, Gianni E, Pulsoni A, Fiorilli M, Casato M, Zignego AL (2016) Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 64(5):1473–1482. CrossRefGoogle Scholar
  22. 22.
    Cacoub P, Vautier M, Desbois AC, Lafuma A, Saadoun D (2017) Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: from interferon-based to direct-acting antivirals era. Liver Int 37:1805–1813. CrossRefGoogle Scholar
  23. 23.
    Tsuge M, Hiramatsu A, Shinohara F, Nakano N, Nakamura Y, Hatooka M, Morio K, Morio R, Kan H, Fujino H, Uchida T, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Ono A, Nagaoki Y, Miki D, Kawaoka T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Ochi H, Nelson Hayes C, Chayama K (2016) Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: a case report. Hepatol Res 46(9):944–948. CrossRefGoogle Scholar
  24. 24.
    Sollima S, Milazzo L, Peri AM, Torre A, Antinori S, Galli M (2016) Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatol (United Kingdom) 55(11):2084–2085. Google Scholar
  25. 25.
    Chowdhury R, Tsen A (2017) Recurrent mixed cryoglobulinemia despite sustained virologic response to treatment: a case report. Am J Kidney Dis 70(2):301–304. CrossRefGoogle Scholar
  26. 26.
    Bonacci M, Lens S, Londoño MC, Mariño Z, Cid MC, Ramos-Casals M, Sánchez-Tapias JM, Forns X, Hernández-Rodríguez J (2017) Virologic, clinical, and immune response outcomes of patients with hepatitis C virus–associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol 15(4):575–583.e1. CrossRefGoogle Scholar
  27. 27.
    Lauletta G, Russi S, Pavone F, Vacca A, Dammacco F (2017) Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia : a single-centre experience. Arthritis Res Ther 2017:1–10. Google Scholar
  28. 28.
    Shimada M, Nakamura N, Endo T, Yamabe H, Nakamura M, Murakami R, Narita I, Tomita H (2017) Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report. BMC Nephrol 18(1):18–21. CrossRefGoogle Scholar
  29. 29.
    Saadoun D, Pol S, Ferfar Y, Alric L, Hezode C, Si Ahmed SN, de Saint Martin L, Comarmond C, Bouyer AS, Musset L, Poynard T, Resche Rigon M, Cacoub P (2017) Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology. 153:49–52.e5. CrossRefGoogle Scholar
  30. 30.
    Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N (2017) Persistent HCV-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antivirals therapy. Hepatology. 65:1769–1770. CrossRefGoogle Scholar
  31. 31.
    Emery JS, Kuczynski M, La D et al (2017) Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol 112(8):1298–1308. CrossRefGoogle Scholar
  32. 32.
    Comarmond C, Garrido M, Pol S, Desbois AC, Costopoulos M, le Garff-Tavernier M, Si Ahmed SN, Alric L, Fontaine H, Bellier B, Maciejewski A, Rosenzwajg M, Klatzmann D, Musset L, Poynard T, Cacoub P, Saadoun D (2017) Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus–induced cryoglobulinemia vasculitis. Gastroenterology. 152(8):2052–2062.e2. CrossRefGoogle Scholar
  33. 33.
    Ghosn M, Palmer M, Najem C, Haddad D, Merkel P, Hogan J (2017) New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy. Clin Nephrol 87(05):261–266. CrossRefGoogle Scholar
  34. 34.
    Santoriello D, Pullela NK, Uday KA, Dhupar S, Radhakrishnan J, D’Agati VD, Markowitz GS (2018) Persistent hepatitis C virus−associated cryoglobulinemic glomerulonephritis in patients successfully treated with direct-acting antiviral therapy. Kidney Int Reports 3(4):985–990. CrossRefGoogle Scholar
  35. 35.
    Comstock E, Kim C, Murphy A et al (2017) Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis. PLoS One:1–14Google Scholar
  36. 36.
    Oleinika K, Mauri C, Salama AD (2018) Effector and regulatory B cells in immune-mediated kidney disease. Nat Rev Nephrol 15:11–26. CrossRefGoogle Scholar
  37. 37.
    Fabris M, Quartuccio L, Sacco S, de Marchi G, Pozzato G, Mazzaro C, Ferraccioli G, Migone TS, de Vita S (2007;(May 2006) B-lymphocyte stimulator ( BLyS ) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology. 46:37–43. CrossRefGoogle Scholar
  38. 38.
    De Rosa M, Azzato F, Toblli JE et al (2018) A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 94(4):788–794. CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Bogdan Obrișcă
    • 1
    • 2
    Email author
  • Roxana Jurubiță
    • 1
    • 2
  • Bogdan Sorohan
    • 1
    • 2
  • Laura Iliescu
    • 2
    • 3
  • Cătălin Baston
    • 2
    • 4
  • Raluca Bobeică
    • 1
  • Andreea Andronesi
    • 1
    • 2
  • Nicolae Leca
    • 5
  • Gener Ismail
    • 1
    • 2
  1. 1.Nephrology Department, Center for Uronephrology and Kidney TransplantationFundeni Clinical InstituteBucharestRomania
  2. 2.“Carol Davila” University of Medicine and PharmacyBucharestRomania
  3. 3.Department of Internal MedicineFundeni Clinical InstituteBucharestRomania
  4. 4.Urology Department, Center for Uronephrology and Kidney TransplantationFundeni Clinical InstituteBucharestRomania
  5. 5.Department of Medicine, Division of NephrologyUniversity of WashingtonSeattleUSA

Personalised recommendations